Biogen Idec, Abbott Announce Positive Top-Line Results From Registrational Trial for Daclizumab HYP in RRMS

Biogen Idec and Abbott announced positive top-line results from SELECT, a global, registrational Phase IIb clinical trial designed to evaluate the investigational compound daclizumab high-yield process in people with relapsing-remitting multiple sclerosis (RRMS) over one year.
Financial Post